Laquinimod senkt Schubrate und Progressionsrisiko - 06 - 2012 - Heftarchiv - AMT
Laquinimod - Wikipedia
Teva drops development of laquinimod - PharmaTimes
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
laquinimod
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
AhR activators - friend or foe? - Hypha Discovery Blogs
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
Active Biotech and Teva together in a Phase II clinical trial against Huntington's disease - Labiotech.eu
Laquinimod | C19H17ClN2O3 | CID 54677946 - PubChem
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Patient enrollment in Phase III trial of laquinimod completed
A Broad Look At Teva's Pipeline (NYSE:TEVA) | Seeking Alpha
EuroBiotech Report—Teva dumps laquinimod, Gilead-Galapagos, GV-Evox, Abivax data and ProQR | Fierce Biotech
Laquinimod - an overview | ScienceDirect Topics
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
AhR activators - friend or foe? - Hypha Discovery Blogs
Teva hit with largest-ever fine under US anti-corruption act - PMLiVE
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
